Navigation Links
Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System
Date:12/4/2008

MENLO PARK, Calif., Dec. 4 /PRNewswire/ -- Long-term data published in EuroIntervention showed that the expected decrease in Mitral Vale Area (MVA) after repair with the MitraClip(R) system to correct mitral regurgitation (MR) is not associated with clinically significant mitral stenosis. Additionally, with two years of follow-up, none of the patients treated with the MitraClip(R) system required surgery for mitral stenosis. At 12 months no important differences were reported between the use of one or two MitraClip(R) devices or based on the etiology of MR.

The analysis was conducted to assess diastolic mitral valve function after percutaneous repair. Echocardiographic measurements of MVA and mean trans- Mitral Valve Gradient (MVG) were made in 96 patients implanted with the MitraClip(R) device. Patients were followed for up to two years.

The MitraClip(R) system is the first commercially available medical device which provides a non-surgical mitral valve repair option for patients suffering from the effects of MR. The MitraClip(R) system is available commercially in Europe and is currently in late stage clinical trials in the United States.

MR affects millions of people worldwide and is the most common type of heart valve insufficiency in Europe and in the United States. The vast majority of patients with significant MR are untreated, which leaves their hearts affected by the chronic volume overload caused by MR, requiring the heart to work harder, and ultimately leading to heart failure.

"It is important to know that the encouraging results from use of the MitraClip(R) system were maintained at two years without mitral stenosis," said Howard C. Herrmann, M.D., director, Interventional Cardiology and Cardiac Catheterization Laboratories at the hospital of the University of Pennsylvania and lead author of the manuscript. "With these results, we have a growing body of evidenc
'/>"/>

SOURCE Evalve, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
2. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
3. Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinsons Disease
4. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
5. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
6. Facet Solutions Announces Completion of 6 Month Follow-Up in US Pilot Study
7. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
8. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Pa. , July 31, 2015 ... fully integrated specialty pharmaceutical company focused on developing, ... the closing of its previously announced underwritten public ... at a public offering price of $11.25 per ... offering included 1,000,000 shares issued upon the exercise ...
(Date:7/31/2015)... and SAN DIEGO , ... its parent company Eisai Co., Ltd. (Headquarters: ... , "Eisai") and Halozyme Therapeutics, Inc. (Headquarters: ... Helen Torley , "NASDAQ: HALO") have signed a ... name: Halaven ® , "eribulin") in combination with Halozyme,s ...
(Date:7/31/2015)... According to a new market ... Analyzers (BIA), Dual-Energy X-ray Absorptiometry (DEXA), Skinfold Calipers, Air ... & Forecast to 2019", published by MarketsandMarkets, the global ... 2014 and is estimated to grow to $1,425.7 Million ... 2014 to 2019. Browse 41 market ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4
... June 16, 2011 Reportlinker.com announces that a ... catalogue: UK CT Systems – ... http://www.reportlinker.com/p0555197/UK-CT-Systems-–-Market-Trend-Till-2016.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging Short Description ... data on the CT systems in UK. It ...
... Inc., a leading provider of software solutions to ... today announced that a number of pharmaceutical industry ... participate in the creation of a set of ... performance data. Each of the initial sponsors will ...
Cached Medicine Technology:Reportlinker Adds UK CT Systems - Market Trend Till 2016 2DecisionView to Create Clinical Trial Enrollment Benchmarks 2DecisionView to Create Clinical Trial Enrollment Benchmarks 3
(Date:8/1/2015)... ... August 01, 2015 , ... Tina Wilcoxson, owner of Freeport Maine’s Royal River ... honor by the National Retail Federation, the largest retail trade association in the world, ... Maine business owners to be named as such. According to the NRF’s website, Retail ...
(Date:8/1/2015)... , ... August 01, 2015 , ... BeverlyD, owner and ... March4thforWellBeing foundation, making hers the very first small business donation to kick off the ... for over thirty years. Her legacy includes a complete line of raw, organic hair ...
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot and warm-season turfgrasses, ... of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for short. Incidentally, ... of this new type of sod, Super-Sod is giving away red Adirondack chairs with ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently touted by Becker’s Healthcare ... health analytics , Jvion continues to disrupt the predictive analytic and big data ... patient and population level illness to drive prevention and better health outcomes. Most ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... at its new True North Conference Center. The medical community, social workers, law ... community may be more aligned in the effort to better understand and combat ...
Breaking Medicine News(10 mins):Health News:Local Retail Advocate Wins National Recognition 2Health News:March4thforWellBeing Foundation Kickoff 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3
... By Jenifer Goodwin HealthDay Reporter , ... that biomarkers in the blood may help diagnose Alzheimer,s ... better treatments. While there are currently no treatments ... disease, the hope is that being able to diagnose ...
... researchers from around the world will be in Milwaukee, ... gaining insights into the brain,s inner workings to better ... and how the brain is altered by neurological diseases ... 350 scientists will attend the Second International Conference on ...
... 13, 2010) - A protein crucial for the immune ... of a devastating form of childhood leukemia called T-cell acute ... the leukemic cells, the study shows, opening a potential avenue ... Led by Iannis Aifantis, PhD, associate professor of ...
... musty odors, along with visual evidence of blue-green algae, ... that harmful cyanotoxins are present in lakes or reservoirs. ... in Midwest lakes, taste-and-odor compounds were found almost every ... a warning that harmful toxins are present. "It ...
... paralysed found that their condition improved after they received a ... in the September issue of the European Journal of ... University in Cairo, Egypt, studied 60 patients with ischaemic stroke ... - who had been left with mild to moderate muscle ...
... Union, its incidence increased by almost 20%, from 2.1 million new ... issue [1] of the European Journal of Cancer (the ... prevention, published today (Monday 13 September). ... number of areas, says a paper by Dr. Jos M. Martin-Moreno ...
Cached Medicine News:Health News:Biomarkers May Aid in Early Diagnosis of Alzheimer's 2Health News:Biomarkers May Aid in Early Diagnosis of Alzheimer's 3Health News:Leading brain scientists meet in Milwaukee to examine how to uncover the brain's secrets 2Health News:Leading brain scientists meet in Milwaukee to examine how to uncover the brain's secrets 3Health News:NYU Langone scientists find key pathway implicated in progression of childhood cancer 2Health News:If the water looks and smells bad, it may be toxic 2Health News:Brain stimulation can help partially paralyzed stroke patients regain use of their muscles 2Health News:Cancer deaths fall, but prevention still lags behind 2Health News:Cancer deaths fall, but prevention still lags behind 3Health News:Cancer deaths fall, but prevention still lags behind 4Health News:Cancer deaths fall, but prevention still lags behind 5
The Lifestream Cholesterol Monitor provides you with a comprehensive tool to help you monitor your cholesterol as part of your wellness program. At a later date, you can purchase the other components...
... The HemoCue Glucose 201+ is the latest ... as the earlier versions, the new system combines ... with a quick turn around time and ease ... stores results and QC results, together with date ...
... using patented, innovative technology, measures a complete ... only 5 minutes from a simple fingerstick. ... get immediate liver function results. The scope ... only advantage to healthcare providers. The physician, ...
CardioChek™ PA Portable Whole Blood Test System...
Medicine Products: